Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03719690
Title	Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)
Acronym	AIM-HN/SEQ-HN
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Kura Oncology, Inc.
Indications	oral squamous cell carcinoma head and neck squamous cell carcinoma nasopharynx carcinoma laryngeal squamous cell carcinoma paranasal sinus cancer pharynx squamous cell carcinoma
Therapies	Tipifarnib
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| GBR \| ESP \| DEU \| BEL \| AUT \| AUS